{"id":3961,"date":"2025-03-31T18:11:54","date_gmt":"2025-03-31T18:11:54","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/etodolac-txt\/"},"modified":"2025-03-31T18:11:54","modified_gmt":"2025-03-31T18:11:54","slug":"etodolac-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/etodolac-txt\/","title":{"rendered":"Etodolac.txt"},"content":{"rendered":"

Etodolac<\/h1>\n

CLINICAL USE <\/H3>
\nNSAID and analgesic

DOSE IN NORMAL RENAL FUNCTION <\/H3>600 mg daily in 1\u20132 divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :287.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>99<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :6\u20137.4\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function, but avoid if possible
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function, but avoid if possible
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but only use if on dialysis

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Use lowest possible dose

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia\n
  • Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac, increased risk of side effects and haemorrhage\n
  • Antibacterials: possibly increased risk of convulsions with quinolones\n
  • Anticoagulants: effects of coumarins enhanced; possibly increased risk of bleeding with heparins and coumarins\n
  • Antidepressants: increased risk of bleeding with SSRIs and venlafaxineAntidiabetic agents: effects of sulphonylureas enhanced\n
  • Anti-epileptics: possibly increased phenytoin concentration\n
  • Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir\n
  • Ciclosporin: may potentiate nephrotoxicity Cytotoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinib\n
  • Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics\n
  • Lithium: excretion decreased Pentoxifylline: increased risk of bleeding\n
  • Tacrolimus: increased risk of nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Take with or after food .ETodoLAC 287

    OTHER INFORMATION <\/H4>Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease \u2013 avoid if possible; if not, check serum creatinine 48\u201372 hours after starting NSAID \u2013 if increased, discontinue therapyIn patients with renal, cardiac or hepatic impairment, especially those taking diuretics, caution is required since the use of NSAIDs may result in deterioration of renal function. The dose should be kept as low as possible and renal function should be monitoredUse normal doses in patients with ERF on dialysis if they do not pass any urineUse with caution in renal transplant recipients \u2013 can reduce intrarenal autocoid synthesisAccumulation of etodolac is unlikely in ARF, CKD or dialysis patients as it is metabolised in the liver.
    \n","protected":false},"excerpt":{"rendered":"

    Etodolac CLINICAL USE NSAID and analgesic DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3961","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3961"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3961\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}